Dr. Stone on Monitoring Patients With AML

Richard M. Stone, MD
Published: Tuesday, Nov 14, 2017



Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses monitoring patients with acute myeloid leukemia (AML).

There are 2 major groups of ways to monitor patients with AML beyond the light microscope, says Stone. The first technique is multiparameter flow cytometry, and the second is based on the mutations in the leukemic cells or specific expression patterns that are present.
 


Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses monitoring patients with acute myeloid leukemia (AML).

There are 2 major groups of ways to monitor patients with AML beyond the light microscope, says Stone. The first technique is multiparameter flow cytometry, and the second is based on the mutations in the leukemic cells or specific expression patterns that are present.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Oncology Briefings™: Updates in Rare Hematology: Advancing Care and Improving Outcomes for Patients with Aplastic AnemiaAug 31, 20181.0
Publication Bottom Border
Border Publication
x